| Autor: |
Tarantino P; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. paolo_tarantino@dfci.harvard.edu.; Department of Oncology and Hematology-Oncology, University of Milano, Milano, Italy. paolo_tarantino@dfci.harvard.edu., Gupta H; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Hughes ME; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Files J; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Strauss S; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kirkner G; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Feeney AM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Li Y; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Garrido-Castro AC; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Barroso-Sousa R; Dasa Institute for Education and Research (IEPD), Brasilia, Brazil.; Dasa Oncology/Hospital Brasilia, Brasilia, Brazil., Bychkovsky BL; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA., DiLascio S; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sholl L; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., MacConaill L; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lindeman N; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Weill Cornell Medicine, New York, NY, USA., Johnson BE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Meyerson M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Jeselsohn R; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Qiu X; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Li R; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Long H; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Winer EP; Yale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital, New Haven, CT, USA., Dillon D; Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA., Curigliano G; Division of Early Drug Development, European Institute of Oncology IRCCS, Milano, Italy., Cherniack AD; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Lin NU; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA. |
Full text from SpringerLink